ATC Group: N02BA Salicylic acid and derivatives

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02BA in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02B Other analgesics and antipyretics
4 N02BA Salicylic acid and derivatives

Group N02BA contents

Code Title
N02BA01 Acetylsalicylic acid
N02BA02 Aloxiprin
N02BA03 Choline salicylate
N02BA04 Sodium salicylate
N02BA05 Salicylamide
N02BA06 Salsalate
N02BA07 Ethenzamide
N02BA08 Morpholine salicylate
N02BA09 Dipyrocetyl
N02BA10 Benorilate
N02BA11 Diflunisal
N02BA12 Potassium salicylate
N02BA14 Guacetisal
N02BA15 Carbasalate calcium
N02BA16 Imidazole salicylate
N02BA51 Acetylsalicylic acid, combinations excl. psycholeptics
N02BA55 Salicylamide, combinations excl. psycholeptics
N02BA57 Ethenzamide, combinations excl. psycholeptics
N02BA59 Dipyrocetyl, combinations excl. psycholeptics
N02BA65 Carbasalate calcium combinations excl. psycholeptics
N02BA67
N02BA71 Acetylsalicylic acid, combinations with psycholeptics
N02BA75 Salicylamide, combinations with psycholeptics
N02BA77 Ethenzamide, combinations with psycholeptics
N02BA79 Dipyrocetyl, combinations with psycholeptics

Active ingredients in N02BA

Active Ingredient

Acetylsalicylic acid combines significant advantages such as strong anti-pyretic, analgesic and anti-inflammatory action, that is the measure of comparison with all the newer NSAIDs.

Carbasalate calcium is a complex of calcium acetyl salicylic acid and urea. It is a thrombocyte aggregation inhibitor. The antithrombotic effect is due to the irreversible acetylating of the enzyme cyclo-oxygenase in the thrombocyte, through which the formation of the prostaglandin thromboxane A2 is inhibited.

Choline salicylate is an anti-inflammatory and antipyretic medication. It is often used in oral gel form for the relief of pain, discomfort, and inflammation caused by common mouth ulcers, cold sores, denture and sore spots, as well as mouth ulcers, and sore spots because of orthodontic devices.

Diflunisal is a difluorophenyl derivate of salicylic acid and a nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic and anti-inflammatory properties. Diflunisal is a prostaglandin synthetase inhibitor. Diflunisal competitively inhibits both cyclooxygenase (COX) -1 and -2, with higher affinity for COX-1, and subsequently blocks the conversion of arachidonic acid to prostaglandin precursors. This leads to an inhibition of the formation of prostaglandins that are involved in pain, inflammation and fever. Diflunisal differs from other salicylates, in that it is not metabolized to salicylic acid, hence it has a longer half-life.

Related product monographs

Document Type Information Source  
 ALKA-SELTZER Effervescent tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 ANADIN Original Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ASA Delayed-release tablet MPI, CA: SPM Health Products and Food Branch (CA)
 AUDAX Ear drops, solution MPI, EU: SmPC Health Products Regulatory Authority (IE)
 DISPRIN Dispersible tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)